Skip to main content
Premium Trial:

Request an Annual Quote

Steven Pinker, Stephen Pentoney, Joseph Hogan

Steven Pinker is among the first 10 participants in the Personal Genome Project, led by Harvard University’s George Church, according to the PGP website. Pinker, who initially chose to remain anonymous, is a professor of psychology at Harvard. The PGP website did not say why he now decided to disclose his participation in the project.

Stephen Pentoney has become vice president of array biochemistry at Illumina, the company said this week. Prior to joining Illumina, he was director of technology management for the molecular diagnostics business center of Beckman Coulter. In the past, he held several research and development positions at Beckman, gaining “significant experience developing automated DNA sequencing chemistry and instrumentation” and other systems. Pentoney holds a PhD in analytical chemistry from the University of California and a BS in chemistry from California State University.

GE Healthcare CEO Joseph Hogan has left the company to take a position as CEO of the power and automation company ABB. GE has named John Dineen, who until now was CEO of GE Transportation, to fill Hogan’s spot.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.